HOME >> BIOLOGY >> NEWS
Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis

SAN DIEGO, CALIF., NOVEMBER 13, 2005 New data, including two-year treatment duration, show a significantly higher proportion of patients with active psoriatic arthritis receiving REMICADE (infliximab) achieved and sustained a high degree of clinical improvement in arthritis, as assessed using the rheumatoid arthritis (RA) definition for "major clinical response," compared with patients receiving placebo. "Major clinical response" is defined as maintenance of a 70 percent improvement in the American College of Rheumatology score (ACR 70) for six continuous months. REMICADE maintenance therapy also resulted in the inhibition of structural damage and significant improvements in functional status and quality of life as maintained over the course of one year. Investigators will present these long-term Phase 2 and 3 study findings this week at the American College of Rheumatology 2005 Annual Scientific Meeting. REMICADE is currently indicated for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis.

"Previous study findings have shown the rapidity and therapeutic intensity of infliximab in treating the joint and skin manifestations associated with active psoriatic arthritis," said Arthur Kavanaugh, MD, Director, Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, and lead study investigator. "These data demonstrate the rapid efficacy of infliximab can be sustained over time, especially as it relates to the arthritic component of this complex disease."

An analysis of two double-blind, placebo-controlled trials, Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) and Induction and Maintenance Psoriatic Arthritis Clinical Trial 2 (IMPACT 2), followed patients for two years (98 weeks) and one year (54 weeks), respectively, and confirmed a significant, high degree of clinical responses in the arthritic component of the disease. Placebo p
'"/>

Contact: Michael Parks
215-325-4010
Centocor, Inc.
16-Nov-2005


Page: 1 2 3 4

Related biology news :

1. Active lifestyle reduces risk of invasive breast cancer
2. Active ingredient in common Chinese herb shown to reduce hypertension
3. Active inbreeding avoidance in wild capuchin monkeys
4. UD awarded $11M for osteoarthritis research and unique mentoring program for women scientists
5. Breakthrough developments in rheumatoid arthritis reported
6. University of Manchester researchers reveal clues to new genes behind rheumatoid arthritis
7. Cartilage discovery offers arthritis hope
8. Rock climbing does not increase risk of osteoarthritis
9. U-M study offers new perspective on nitric oxide signaling in rheumatoid arthritis
10. Turmeric prevents experimental rheumatoid arthritis, bone loss, University of Arizona study shows
11. Can Gleevec help patients with rheumatoid arthritis?

Post Your Comments:
(Date:8/19/2014)... treat pain, but its effect on pain following ... recent study reported on the Neural Regeneration ... models of an avulsion injury to the left ... pain) were given electroacupuncture stimulation at bilateral Quchi ... After electroacupuncture therapy, chronic neuropathic pain in the ...
(Date:8/19/2014)... forms, they have not been widely used due to ... the University of Surrey and Trinity College Dublin have ... graphene, to create a flexible sensor that is sensitive ... , Once treated, the rubber bands remain highly ... imparts an electromechanical response on movement the team ...
(Date:8/18/2014)... , August 19, 2014 ... biometric authentication in smart devices  Trustonic, ... for smart devices, and Fingerprint Cards AB (FPC) ... of FIDO Ready™ secure biometric authentication on connected ... touch fingerprint sensors (FPC1020, FPC1021 and FPC1150) and ...
Breaking Biology News(10 mins):Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 2Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 4
(Date:8/18/2014)... , Aug. 18, 2014 BioElectronics ... advanced consumer medical devices said that its ... interviewed by CEOLIVE.TV as part of its ... interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... explains to investors the unique advantages of ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
(Date:8/18/2014)... 2014 TNI BioTech, Inc. (OTC-BB: TNIB) ("we" ... and marketing of innovative therapies for autoimmune diseases in ... a second notice of TNI BioTech,s annual meeting of ... Noreen Griffin , founder and CEO of TNI ... participation in the Annual Meeting. On behalf of our ...
(Date:8/18/2014)... , 18. August 2014 Vier ... eine internationale klinische Studie auf, in der ... Linse soll das Sehvermögen bei allen Entfernungen ... Operation möglicherweise keine Lese- oder Gleitsichtbrille mehr ... Namen FluidVision Accommodating Intraocular Lens ...
Breaking Biology Technology:BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
Cached News: